California Initiative to Advance Precision Medicine Advisory Council
Meet California Precision Medicine Advisory Council.
The Newsom Administration created a new California Precision Medicine Advisory Council to provide high-level guidance to the Governor’s Office of Planning and Research on matters relating to the CIAPM program. Members were selected by the Governor and the Legislature, and are experts in precision medicine. They represent patient advocacy and community groups, academia, private industry, health policy, clinical providers, venture capital and philanthropy. They are experts in the areas of data science, bioinformatics, pharmacology, community engagement, medical devices, and public health.
Dr. Nadine Burke Harris is an award-winning physician, researcher and advocate dedicated to changing the way our society responds to one of the most serious, expensive and widespread public health crises of our time: childhood trauma. She was appointed as California’s first-ever Surgeon General by Governor Gavin Newsom in January 2019. Her career has been dedicated to serving vulnerable communities and combating the root causes of health disparities.
She founded the Center for Youth Wellness in one of San Francisco's most underserved communities, Bayview-Hunters Point, an organization leading the effort to advance pediatric medicine, raise public awareness, and transform the way society responds to children exposed to Adverse Childhood Experiences (ACEs) and toxic stress. She also founded and led the Bay Area Research Consortium on Toxic Stress and Health, to advance scientific screening and treatment of toxic stress.
Ysabel Duron is the Founder/CEO of the California based Latino Cancer Institute working to eliminate the Latino cancer burden nationwide by driving equitable access, research and policy.
Duron was an award-winning TV journalist for 43 years in the San Francisco Bay Area and elsewhere, but stepped away in 2013 to continue her role as a patient advocate and voice for the Latino community.
A cancer survivor, she serves both on the Institutional Review Board of the NIH All of Us Research Program, and most recently joined the Board of California Institute for Regenerative Medicine, a state taxpayer funded initiative to support stem cell research.
She was inducted into the National Association of Hispanic Journalists Hall of Fame in 2009, named one of the 25 most outstanding Hispanics in the Bay Area in 2005 and honored with the W.E.B. DuBois from the SJ Chapter of the NAACP in 2011, amongst other honors that reflect her community engagement.
Dr. Oliver Keown is a UK-trained physician, scientist and former policy advisor turned healthcare and medical technologies venture capital investor with Intuitive Ventures. Prior to joining Intuitive, he was a VC investor with GE Ventures, driving startup deal-flow in the Bay Area and beyond across HealthTech, life science and MedTech domains.
In past roles Oliver has advised and supported a range of US and international healthcare innovation projects across technology, policy, commercial, and academic fields. Early in his career he worked as a junior doctor in the UK National Healthcare Service across a variety of medical and surgical disciplines. He holds an MD and a Bachelor's degree in Pharmacology from the University of Edinburgh, Scotland.
Dr. Kenneth Kim received his MD from Harvard Medical School, completed a fellowship at the MIT Sloan School of Management, and received internal medicine and allergy/immunology training at UCLA. He has served on the clinical faculty both at UCLA and UC Irvine for over 15 years. He has been a medical monitor, consultant, and investigator on over 600 clinical trials, having published over 30 research articles and 50 abstracts in peer-reviewed journals. He is a nationally recognized expert in the areas of early stage clinical research, ethnobridging drug development strategy, influenza challenge, mold allergy, and latex allergy.
He has founded numerous health care services businesses, including a 200+ employee clinical research organization which he transitioned to private equity. He is currently the medical director of Ark Clinical Research and a strategic investor in a variety of startups, while also maintaining a private allergy and asthma practice in Southern California.
Clara Lajonchere, PhD
Dr. Clara Lajonchere is the Deputy Director for the UCLA Institute for Precision Health, Co-Director of the Clinical Neurogenomics Research Center and Adjunct Professor of Neurology in the David Geffen School of Medicine at UCLA. Dr. Lajonchere's background reflects a wide range of professional, clinical, and research activities across central nervous system disorders. She has spent her career on cross-cutting issues in psychiatric genetics and translational medicine. Through the UCLA Institute for Precision Health, Dr. Lajonchere is working collaboratively with thought leaders across the state of California to advance precision medicine and improve outcomes for patients. She currently serves as chair of the California Precision Medicine Advisory Council for the Governor's Office of Planning and Research. Prior to UCLA, Dr. Lajonchere held faculty appointments at the USC Keck School of Medicine where she served as Principal Investigator and Director of the NIH Center for Genomic and Phenomic Studies in Autism and conducted research on models for inclusion of underserved populations in biomedical research. She also served as VP of Clinical Programs for Autism Speaks for over a decade where she oversaw a diverse portfolio of basic science and clinical programs. She currently consults for several tech start-ups in the autism space focused on AI, robotics, and targeted therapeutics.
Dr. Yvonne (Bonnie) A. Maldonado is Professor in the Departments of Pediatrics and Epidemiology and Population Health, Chief of the Division of Infectious Diseases, and Senior Associate Dean for Faculty Development and Diversity at Stanford University School of Medicine. Her research activities have included the epidemiology and prevention of viral infections such as rotavirus, measles, mumps, rubella, polio and pediatric HIV infection. Her research is conducted internationally in Zimbabwe and Mexico, as well as in the United States. She has written over 200 articles in peer-reviewed journals, and 50 book chapters on these topics. In 1989, Dr. Maldonado received the Epidemic Intelligence Service Alumni Award from the Centers for Disease Control and Prevention, and she was inducted into the Multicultural Alumni Hall of Fame at Stanford University in 2001 and the Stanford Medical Alumni RISE (Reach, Inspire, Serve and Engage) award in 2018. She is a Fellow of the American Academy of Pediatrics, a member of the Society for Pediatric Research, the Pediatric Infectious Disease Society and the American Public Health Association. Dr. Maldonado has devoted substantial effort to teaching and training activities at Stanford University as well as in the national and international setting. Throughout her career, she has invested heavily in her commitment to improving cultural and gender diversity at all levels.
Dr. Fatima Muñoz is the Director of the Department of Research and Health Promotion at San Ysidro Health (SYHealth), a high performing Federally Qualified Health Center (FQHC) providing care to over 105,000 patients throughout San Diego County. Fatima completed her medical training in Mexico and earned a Master's in Public Health from Universidad Autónoma de Baja California. She possesses over 15 years of clinical research experience working in health promotion programs and epidemiological research studies, specifically among underserved populations. Fatima’s expertise in public health issues spans both sides of the U.S.-Mexico border with emphasis in the elimination of health disparities. Her award winning research portfolio includes: chronic disease, HIV prevention and treatment, cervical and breast cancer, and the impact of bi-national access to care on health policy. Most recently, SYHealth was awarded the All of Us Research Program from the National Institute of Health. It is only one of six FQHCs west of the Mississippi that is part of this Program and Fatima is the Principal Investigator for SYHealth. In this capacity, she and her team have been contributing in the development and implementation of the program Spanish speaking participants.
As VP and Head of Diagnostics, Dr. Hakan Sakul leads Pfizer's company-wide Diagnostics efforts. Sakul worked in the biotech industry in human genetics and statistical genetics fields early in his career before moving to Parke-Davis Pharmaceuticals to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Parke-Davis with Pfizer, he has held positions of increasing responsibility, including Director/Site Head for Clinical Pharmacogenomics, Senior Director roles in Molecular Profiling and Translational Oncology, and most recently as Executive Director of Diagnostics. After receiving BS and MSc degrees from Ankara University in Turkey, and a PhD in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, he conducted postdoctoral studies at the University of California, Davis. He is the author of over 30 refereed scientific articles as well as many other papers, abstracts, and book chapters. Sakul is keenly interested in diagnostics and related medical technologies to advance precision medicine for the improvement of individualized healthcare.
Dr. Mary Anne Schultz is an accomplished Senior Executive and Consultant with more than 40 years of success across the nursing service, nursing education, informatics, and clinical/business intel venues. Her broad areas of expertise include data analysis, program evaluation, and evidence-based practices customized to a system's health care client. Throughout her executive career, Mary Anne has held faculty and leadership positions within the California State University and University of California systems, and $chultz & Associates. Dr. Schultz is a Professor, Informaticist and former Chair for the Nursing Department at California State University, San Bernardino. She holds a PhD in Nursing Systems and Economics from UCLA, an MBA from Claremont Graduate University, and a certificate in Health Informatics from UC Davis.
Keith Yamamoto, PhD
Dr. Keith R. Yamamoto is Vice Chancellor for Science Policy and Strategy, and Director of Precision Medicine at UCSF. A UCSF researcher since 1973, he is a leader in determination of gene regulatory mechanisms. He has led or served on national committees focused on public and scientific policy, public understanding of science, science education, open science, and peer review. He chairs the Coalition for the Life Sciences and sits on the National Research Council Governing Board Executive Committee, the Board of Directors of Research!America, the Board of Directors of the Public Library of Science, the Governing Board of the California Institute for Regenerative Medicine, and the Advisory Board for Lawrence Berkeley National Laboratory. As Chair of the National Academy of Sciences Board on Life Sciences, Dr. Yamamoto created the study committee that produced Toward Precision Medicine, which enunciated the precision medicine concept, and he helped lead efforts in the White House, Congress, Sacramento, and UCSF to implement it. He was elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and is a fellow of the American Association for the Advancement of Science.
For more information about this content, please contact: